

February 18, 2022

Adrian Gottschalk  
Chief Executive Officer  
Foghorn Therapeutics Inc.  
500 Technology Square, Suite 700  
Cambridge, MA 02139

Therapeutics Inc.  
Statement on Form S-3  
2022

Re: Foghorn  
Registration  
Filed February 14,  
File No. 333-262711

Dear Mr. Gottschalk:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jordan Nimitz at 202-551-5831 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc:

Marc Rubenstein, Esq.